Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iAdhere: Adherence to LTBI Treatment With Weekly Rifapentine and Isoniazid
NCT01582711Phase 3Completed
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Sep 2012
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of isoniazid and rifapentine in Tuberculosis (TB) (3 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Treatment Completion Rate at 16 weeks. Started Sep 2012; status: completed.
02
Drugs
isoniazidrifapentine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT01582711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01582711.